Sign In
Buy ANIP
$75.23
+0.580 (+0.777%)
At Close: Jun 03, 2026
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates
09:06am, Tuesday, 06'th Aug 2024
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $1.28 per share a year ago.
ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance
06:50am, Tuesday, 06'th Aug 2024
BAUDETTE, Minn., Aug. 06, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the three months ended Ju
Seeking Clues to ANI (ANIP) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:22am, Monday, 05'th Aug 2024
Besides Wall Street's top -and-bottom-line estimates for ANI (ANIP), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarte
ANIP has three 505(b)(2) NDA submissions under FDA review, including oral liquid terazosin, female testosterone drug, and oral liquid hydrochlorothiazide. Potential peak sales for Tezruly and hydrochl
ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder
07:00am, Monday, 15'th Jul 2024
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administratio
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP
07:00am, Tuesday, 02'nd Jul 2024
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for t
SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.
09:40pm, Wednesday, 26'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. ("Alimera" or
ANI Pharmaceuticals' CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner
07:00am, Tuesday, 25'th Jun 2024
Recognized for outstanding entrepreneurial leadership, driving impressive growth, and patient impact Recognized for outstanding entrepreneurial leadership, driving impressive growth, and patient impac
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
06:50am, Monday, 24'th Jun 2024
Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue Ad
ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
01:50am, Monday, 10'th Jun 2024
ANIP's potential royalty revenue from two upcoming drug applications could generate $415 million annually, not reflected in the current share price. ANI Pharmaceuticals' legal action against CG Oncolo
ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference
04:30pm, Wednesday, 29'th May 2024
BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024 J
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
11:00am, Monday, 20'th May 2024
NEW YORK , May 20, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) on behalf of the company's shareholders. The investigation
Down -6.19% in 4 Weeks, Here's Why ANI (ANIP) Looks Ripe for a Turnaround
10:36am, Monday, 20'th May 2024
ANI (ANIP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earni
ANI Pharmaceuticals Announces the Launch of Kionex® Suspension
06:50am, Monday, 20'th May 2024
BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP) for
Gilead (GILD) Announces Positive Interim Results on PBC Drug
12:00am, Monday, 20'th May 2024
Gilead Sciences, Inc. (GILD Quick QuoteGILD - Free Report) announced positive interim results from the ongoing ASSURE study on pipeline candidate seladelpar.ASSURE is an open-label study evaluating th
